News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Almac Group Further Enhance 3rd Party Logistics Commercial Support Services For Niche / Orphan Drugs


11/18/2013 10:12:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

18 November 2013 -- Almac, a leading provider of contract services to the global Pharmaceutical and Biotech industries, is pleased to announce the release of an enhanced 3rd Party Logistics (3PL) Customer Billing Application.

In response to growing client demand for fully integrated end to end support of EU product launches, from import testing, country specific packaging, QP release, online ordering, direct to pharmacy distribution and financial services, Almac have enhanced their customer billing software to facilitate a seamless invoicing process on behalf of 3PL clients.

3PL orders, received directly from hospitals / clinics / pharmacies, for niche/ orphan drug products, will now be processed, dispatched, and automatically invoiced on the client’s behalf. The process will be completed by reconciliation of payments to the client’s EU account, as well as debtor follow up.

David Downey, VP Commercial Operations of Almac explains “With our client partners, we have successfully launched many high-value, orphan drug / niche products into the European market. With this enhancement to our customer billing application, we can alleviate the client’s administrative burden, by essentially becoming an extension of their supply chain team and assist in managing cash receipts and debtor follow up. Particularly for US based clients with no EU operational footprint, this end to end service provides a compelling business case to partner with an experienced EU solutions provider. ”

About Almac

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,300 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with US operations based in Pennsylvania, North Carolina and California.

To learn more about Almac please visit www.almacgroup.com, e-mail info@almacgroup.com or follow us on Twitter at https://twitter.com/AlmacGroup.

For media enquiries, please contact Tristan Jervis at De Facto Communications on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES